10-Q · May 8, 2026
Nexalin Technology, Inc. experienced significant revenue growth in Q4 2026, with reported revenue of $171,895, compared to $41,015 in the same quarter last year, marking a 319% increase. However, the company continued…
Earnings analysis · 10-Q
NXL earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include current-period income statement, balance-sheet, segment, or cash-flow figures, so no reported Q2 2026 revenue, margin, EPS, or free-cash-flow trend can be quantified from the…
Read full summary
The provided 10-Q excerpt does not include current-period income statement, balance-sheet, segment, or cash-flow figures, so no reported Q2 2026 revenue, margin, EPS, or free-cash-flow trend can be quantified from the supplied text. The filing adds significant financing and listing pressure: Nasdaq delisting proceedings are pending after failure to meet the $1.00 bid-price requirement, and delisting could eliminate ATM access. Two material internal-control weaknesses remain, while the PONM acquisition introduces execution, related-party, and dilution risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
PONM acquisition completed
The Company completed the PONM, Inc. acquisition on May 14, 2026 for aggregate consideration of approximately $1.3 million, including an exclusive licensed technology asset recorded at approximately $700,000.
-
Reverse-split plan approved
The Board approved a 30-to-1 reverse stock split ratio after stockholders authorized reverse splits ranging from 1-for-2 to 1-for-100, subject to an aggregate maximum of 1-for-250.
-
PONM consideration issued
The Company issued 959,016 common shares with an initial fair value of approximately $725,000 as the first tranche of PONM acquisition consideration.
What to watch
-
Pending Nasdaq delisting proceeding
Nasdaq determined on July 24, 2026 that the Company had not regained compliance with the $1.00 minimum closing bid-price requirement after the initial 180-calendar-day compliance period expired on July 20, 2026. The Company requested a hearing, but continued listing is not assured and delisting could materially reduce liquidity and financing access.
-
Potential loss of ATM financing
If delisted, the Company expects to lose access to its ATM program because Form S-3 eligibility depends on continued national-exchange listing. The Company also states there is substantial doubt about its ability to continue as a going concern, potentially delaying or eliminating planned activities including its pivotal insomnia clinical trial.
-
Material internal-control weaknesses
The 10-Q identifies 2 material weaknesses in internal controls: insufficient segregation of duties and inadequate IT access controls. Management says remediation depends on hiring qualified personnel subject to budget limitations, and that redesign and implementation may be costly and time consuming.
-
PONM execution and dilution risk
The PONM technology requires additional development and customization, while the collaboration agreement with GLV has an initial term of only 24 months. Approximately $387,000 of acquisition consideration remained unpaid at June 30, 2026, and the number of future shares may increase substantially if the stock price declines or a reverse split occurs.
Management's outlook
No quantitative revenue or EPS outlook was disclosed in the provided 10-Q text; numeric guidance may be deferred to the earnings release or call.
Earlier filings 3
10-K · March 25, 2026
Nexalin positions itself as a bioelectronic medical-device company focused on next-generation (Gen-2 SYNC, Gen-3 HALO) neurostimulation headsets and a virtual clinic model; management highlights FDA Q-Submission…
10-Q · May 13, 2025
Nexalin reported Q1 2025 revenue of $41,015 (beat consensus $35,000 by ~17%) and improved revenue sequentially from $27,179 in Q4 2024 (+50.9%). Gross margin contracted to 66.9% from 72.4% in Q4 2024 and net loss…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.